Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · SYNCOMF

SYNCOM FORM.

HealthcarePharmaceuticals & Biotechnology₹2074 cr market cap
₹22.09 ▲ +0.05% today As of 19 Nov 2026
52-week low ₹10.3052-week high ₹26.18

-15.7% from the 52-week high · +114.4% above the low

Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh and currently employs 799 full-time employees. The firm is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. The company is also engaged in the renting of properties. The company manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The firm's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.

The short version. SYNCOM FORM. reported revenue of ₹142 crore for Sep 2026, up 16.4% from a year earlier. Net profit was ₹27 crore (up 58.8% year on year). Return on equity was 18.4% in Mar 2026. Promoter holding was 50.57% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

SYNCOM FORM. trades 15.7% below its 52-week high and 114.4% above its 52-week low.

Change over period: —

1M+3.1%
3M+44.0%
6M+56.5%
1Y+35.0%

2 · The business

Is it growing?

Sales, year on year+16.4%

Sep 2026 revenue of ₹142 cr.

Profit, year on year+58.8%

Sep 2026 net profit of ₹27 cr.

Net margin18.8%

5.2 pts higher than a year earlier.

3-year growth56.2% profit

Revenue compounded at 29.6% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue142126135115122117149128
Net profit2725251917161813
Net margin %18.819.818.616.413.613.511.910.2
EPS (₹)0.280.260.270.20.180.170.190.14

Annual

FY2026FY2025FY2024FY2023
Revenue489465263224
Net profit76492520
Net margin %15.610.69.68.9
EPS (₹)0.810.530.270.21

3 · The quality

How well does it turn capital into profit?

Return on equity was 18.4% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %18.414.48.87.8
Return on capital %23.818.812.911.2
EBITDA margin %20.914.815.614.3
Net margin %14.710.29.18.4

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR29.6%—
Profit CAGR56.2%—
Debt to equity0.00
Interest cover88.6x
Current ratio3.18
P/E ratio21.3

4 · The owners

Who holds it, and are they adding?

Promoter holding50.57%

Unchanged over 8 quarters.

Foreign institutions2.22%

Up 2.09 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter50.5750.5750.5750.5750.5750.5750.5750.570.0
FII0.130.110.410.10.260.210.352.22+2.09
DII000000000
Public49.349.3249.0249.3349.1749.2149.0847.2-2.1

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.06% of NAV
  • Bandhan BSE Healthcare Index Fund0.06% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for SYNCOM FORM. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about SYNCOM FORM.

What is the SYNCOM FORM. share price?

SYNCOM FORM. (SYNCOMF) last closed at ₹22.09, up 0.05% on the day. Its 52-week range is ₹10.30 to ₹26.18.

What is the market cap of SYNCOM FORM.?

SYNCOM FORM. has a market capitalisation of about ₹2,074 crore. Its price-to-earnings ratio is 21.3.

How are SYNCOM FORM.'s latest results?

SYNCOM FORM. reported revenue of ₹142 crore for Sep 2026, up 16.4% from a year earlier. Net profit was ₹27 crore (up 58.8% year on year). Return on equity was 18.4% in Mar 2026. Promoter holding was 50.57% in Sep 2026, up 0.00 points over 8 quarters.

Who owns SYNCOM FORM.?

As of Sep 2026, shareholding was: Promoter 50.57%, FII 2.22%, Public 47.2%.

How many mutual funds hold SYNCOM FORM.?

2 mutual fund schemes held SYNCOM FORM. in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 09 Sep 2022 · Final Dividend - Rs. 0.03
  • 21 Sep 2017 · Dividend - Rs. 0.02
  • 22 Sep 2016 · Dividend - Rs. 0.02
  • 16 Sep 2015 · Dividend - Rs. 0.02
  • 18 Sep 2014 · Dividend - Rs. 0.02

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.